Experiment Overview
| Repository ID: | FR-FCM-Z58Z | Experiment name: | Human 21 week gestation liver phenotype | MIFlowCyt score: | 53.27% |
| Primary researcher: | Marcus Muench | PI/manager: | Marcus Muench | Uploaded by: | Marcus Muench |
| Experiment dates: | 2018-08-01 - 2018-08-03 | Dataset uploaded: | Apr 2022 | Last updated: | Sep 2022 |
| Keywords: | [hematopoiesis ] [Hematopoietic cells] [Fetal liver] [Hepatoblasts] [Liver Sinusoidal Endothelial Cells] | Manuscripts: | |||
| Organizations: |
Vitalant Research Institute, San Francisco, CA (USA)
|
||||
| Purpose: | Cell-surface antigen screening was performed on human fetal liver cells by flow cytometry to provide phenotype data on multiple cell populations. | ||||
| Conclusion: | The flow cytometric screening of cell surface antigens provides phenotype data for multiple cell types found in the human midgestation liver. These data are valuable to researchers studying liver ontogeny, normal development of hepatocytic cells, and the development of liver cancer. This work provides a resource for protein expression data for researchers studying human developmental hepatology, hematology, immunology, and liver sinusoidal endothelial cell biology. | ||||
| Comments: | All data are derived from antibody stainings of a single liver specimen that was prepared by enzymatic dissociation and depleted of CD235a+ erythrocytes using immunomagnetic beads. With the exception of control samples, all experimental groups were stained with CD45-FITC, CD235a-FITC, CD326-APC, and CD14-PE-Cy7 antibodies in addition to the 332 antigens stained with PE-conjugated antibodies. | ||||
| Funding: | This work was supported by the California Institute for Regenerative Medicine, grant number DISC1-08855. C.N. was supported by a Bridges to Stem Cell Research and Therapy Award EDUC2-08400 from the California Institute of Regenerative Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the California Institute for Regenerative Medicine or any other agency of the State of California. | ||||
| Quality control: | None | ||||
